Insulin Program
Diabetes
Pre-clinicalActive
Key Facts
About Biolingus
Biolingus is pioneering a novel drug delivery platform focused on the sublingual (under-the-tongue) administration of large molecule drugs, including peptides, proteins, and vaccines. Its core technology is designed to protect biologics from degradation in the gut and facilitate absorption directly into the bloodstream via the oral mucosa, potentially eliminating the need for painful and costly injections. The company is advancing a pipeline of internal and partnered programs, targeting significant markets in diabetes, obesity, and immunology. As a private, pre-revenue entity, Biolingus's success hinges on validating its platform in clinical trials and securing strategic partnerships to fund development and commercialization.
View full company profileTherapeutic Areas
Other Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| AdOral® Insulin | Adocia | Preclinical |
| Oral Insulin | Premas Biotech | Phase 3 |
| PRX-3140 | Nanopharmaceutics | Clinical |
| Insulin Aspart Biosimilar | Meitheal Pharmaceuticals | Preclinical |
| Insulin Glargine Biosimilar | Meitheal Pharmaceuticals | Preclinical |
| Insulin Lispro Biosimilar | Meitheal Pharmaceuticals | Preclinical |
| Liraglutide Injection | Meitheal Pharmaceuticals | Approved |
| Diabetes Clinical Trials | DM Clinical Research | Not Specified |
| Diabetes Therapeutic | Housey Pharmaceutical Research Laboratories | Not specified |
| Diabetes Research | Evidation Health | Research |
| Injectable HDV-Rapid Acting Insulin (Open Label, MoA) | Diasome Pharmaceuticals | Phase 2 |
| Glucose-Responsive Insulin Receptor Agonist | Protomer Technologies | Pre-clinical (integrated into Lilly pipeline) |